Compare EOG Resources Inc (EOG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Gilead Sciences, Inc. — how do they compare? EOG Resources Inc trades at $138.94 (market cap $73.22B), while Gilead Sciences, Inc. trades at $133.03 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 2.2× EOG Resources Inc's market cap, and EOG Resources Inc pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| EOG | GILD | |
|---|---|---|
Market Cap | $73.22B | $163.51B |
Sector | Energy | Health |
52-Week High | $149.89 | $155.80 |
52-Week Low | $101.78 | $108.22 |
Enterprise Value | $77.68B | $178.05B |
Dividend Yield | 2.97% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $138.01, down 1.15% on the day, with a bullish technical signal from moving averages and strong analyst support. The company maintains robust profitability with a net income margin of 23.39% and has beaten earnings estimates for the last three quarters. Recent news highlights its valuation discount and operational strength, with a consensus price target of $156.40 suggesting upside potential.
The outlook for EOG is positive, driven by consistent earnings beats, solid cash flow, and a favorable analyst consensus. Key risks include oil price volatility and elevated capital expenditures. The stock presents an opportunity for growth investors seeking exposure to a high-quality energy producer trading below target prices.
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
